Neurodyn Inc. acquires Memogain for Dementia in Alzheimer’s Disease
Neurodyn Inc. announced that it has acquired from Galantos Pharma GmbH, Mainz, Germany all assets related to their Alzheimer’s prescription drug candidate – Memogain®. Memogain® has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in late 2013. The terms of the acquisition were not disclosed.
“We are very pleased to complete this acquisition. Memogain® is a significant improvement over existing Alzheimer’s drugs, and is staged for immediate entry into clinical trials. It has the potential to follow a fast-track regulatory pathway in both the US and Europe.” said Kenneth Cawkell, Neurodyn CEO.
Memogain® is a patented improvement on the generic drug, galantamine, (Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine). Galantamine, a plant-derived compound, is widely prescribed to enhance cognition for the treatment of mild to moderateAlzheimer’s disease, but has a limited capacity for brain penetration and significant side effects that limit its effectiveness. Memogain® was developed to have a much higher bioavailability in the brain, without the negative gastro-intestinal side effects that limit patient acceptance.
Neurodyn will also investigate the potential for Memogain® to decrease the amyloid plaque burden associated with Alzheimer’s disease and to induce new cell growth in regions of the brain affected by the disease.
Other news from the department business & finance
